Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Fins on sedar

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Feb 29, 2024 2:44pm

138 Views

Post# 35907238

RE:RE:RE:RE:RE:Fins on sedar

Mgmt also must have used q4 as a correction qtr instead of restating q1,q2,q3. My estimate.....

Qtr ending	Sales to Abbvie	R+F settlement	Other income	Total Revenue + Other income
Oct 23	27,964	0	3,852	31,816
Jul 23	6,815	0	16	6,831
Apr 23	0	59,514	1,388	60,902
Jan 23	0	0	1,467	1,467
Total	34,779	59,514	6,723	101,016

biorun wrote: The revenue was deemed by the auditors to be related to close out settlement with R&F, not from product sales (which would be reported on the revenue line), so the revenue is captured in "other income" lower down on the table.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale